Apogee Therapeutics, Inc.
APGE
$69.47
-$0.56-0.79%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -65.02M | -66.10M | -55.34M | -67.22M | -49.02M |
| Total Depreciation and Amortization | 406.00K | 399.00K | 207.00K | 76.00K | 48.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 11.20M | 10.51M | 9.60M | 5.38M | 2.72M |
| Change in Net Operating Assets | -837.00K | -6.84M | -2.95M | -5.96M | 3.73M |
| Cash from Operations | -54.26M | -62.03M | -48.48M | -67.71M | -42.52M |
| Capital Expenditure | 0.00 | -768.00K | -4.32M | 1.00K | -751.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 17.95M | 78.89M | 17.30M | 46.37M | -145.63M |
| Cash from Investing | 17.95M | 78.13M | 12.98M | 46.37M | -146.38M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 19.74M | 1.18M | 622.00K | 44.36M | 383.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 19.74M | 1.18M | 622.00K | 44.36M | 383.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -16.57M | 17.28M | -34.87M | 23.01M | -188.52M |